Palatin Technologies 
Welcome,         Profile    Billing    Logout  
 6 Products   15 Diseases  6 Products   6 Trials   218 News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PL-3994 / Palatin Technologies
NCT04318145: Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Recruiting
2
55
US
PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994, PL-3994 Aqueous Intravenous Solution Single Dose
Palatin Technologies
Heart Failure With Preserved Ejection Fraction
03/22
03/23
Vyleesi (bremelanotide) / Palatin Technologies
NCT04179734: Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

Completed
4
40
Europe
Bremelanotide, Placebo
Imperial College Healthcare NHS Trust, AMAG Pharmaceuticals, Inc.
Hypoactive Sexual Desire Disorder
10/20
10/20
NCT06867835: Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

Not yet recruiting
4
10
NA
Vyleesi (Bremelanotide Injection)
Cosette Pharmaceuticals, Inc.
Lactating Mother
07/25
10/25
KD-BMT-301, NCT04943068: A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Completed
3
193
RoW
Bremelanotide, Placebo
Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
05/23
05/23
ACTRN12615001059550: A Within-Subject Single Dose Trial on the Effects of Bremelanotide on Social Cognition and Behaviour

Recruiting
2
60
 
University of Sydney, Simons Foundations
Autism Spectrum Disorder
 
 
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
BMT-801, NCT06565611: A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity

Active, not recruiting
2
108
US
bremelanotide, tirzepatide
Palatin Technologies, Inc
Obesity
02/25
03/25
PL8177 / Palatin Technologies
NCT04105452: Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)

Not yet recruiting
2
40
NA
PL8177
Palatin Technologies
Non-infectious Uveitis
05/20
09/20
2019-003197-24: Study of the effect of PL-8177 on inflammatory onset and resolution in Healthy Volunteers

Not yet recruiting
2
45
Europe
prednisolone, PL8177, Solution for injection in pre-filled syringe, Tablet, Prednisolone Tablets BP 5mg
Palatin Technologies, Inc., Palatin Technologies, Inc.
Inflammatory Onset and Resolution, Blister induction and effect of PL8177 on inflammation, Body processes [G] - Immune system processes [G12]
 
 
PL8177-205, NCT05466890: Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Active, not recruiting
2
16
US
PL8177 Placebo, Placebo, PL8177, Active study medication
Palatin Technologies, Inc
Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
02/25
03/25
PL9643 / Palatin Technologies
MELODY-1, NCT05201170: A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Completed
3
575
US
Vehicle Ophthalmic Solution, Control, PL9643 Ophthalmic Solution, Active study medication
Palatin Technologies, Inc
Dry Eye, Dry Eye Syndromes
09/23
11/23
PL-3994 intravenous / Palatin Technologies
No trials found
PL8331 / Palatin Technologies
No trials found
PL9654 / Palatin Technologies
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PL-3994 / Palatin Technologies
NCT04318145: Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Recruiting
2
55
US
PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994, PL-3994 Aqueous Intravenous Solution Single Dose
Palatin Technologies
Heart Failure With Preserved Ejection Fraction
03/22
03/23
Vyleesi (bremelanotide) / Palatin Technologies
NCT04179734: Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

Completed
4
40
Europe
Bremelanotide, Placebo
Imperial College Healthcare NHS Trust, AMAG Pharmaceuticals, Inc.
Hypoactive Sexual Desire Disorder
10/20
10/20
NCT06867835: Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

Not yet recruiting
4
10
NA
Vyleesi (Bremelanotide Injection)
Cosette Pharmaceuticals, Inc.
Lactating Mother
07/25
10/25
KD-BMT-301, NCT04943068: A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Completed
3
193
RoW
Bremelanotide, Placebo
Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
05/23
05/23
ACTRN12615001059550: A Within-Subject Single Dose Trial on the Effects of Bremelanotide on Social Cognition and Behaviour

Recruiting
2
60
 
University of Sydney, Simons Foundations
Autism Spectrum Disorder
 
 
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
BMT-801, NCT06565611: A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity

Active, not recruiting
2
108
US
bremelanotide, tirzepatide
Palatin Technologies, Inc
Obesity
02/25
03/25
PL8177 / Palatin Technologies
NCT04105452: Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)

Not yet recruiting
2
40
NA
PL8177
Palatin Technologies
Non-infectious Uveitis
05/20
09/20
2019-003197-24: Study of the effect of PL-8177 on inflammatory onset and resolution in Healthy Volunteers

Not yet recruiting
2
45
Europe
prednisolone, PL8177, Solution for injection in pre-filled syringe, Tablet, Prednisolone Tablets BP 5mg
Palatin Technologies, Inc., Palatin Technologies, Inc.
Inflammatory Onset and Resolution, Blister induction and effect of PL8177 on inflammation, Body processes [G] - Immune system processes [G12]
 
 
PL8177-205, NCT05466890: Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Active, not recruiting
2
16
US
PL8177 Placebo, Placebo, PL8177, Active study medication
Palatin Technologies, Inc
Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
02/25
03/25
PL9643 / Palatin Technologies
MELODY-1, NCT05201170: A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Completed
3
575
US
Vehicle Ophthalmic Solution, Control, PL9643 Ophthalmic Solution, Active study medication
Palatin Technologies, Inc
Dry Eye, Dry Eye Syndromes
09/23
11/23
PL-3994 intravenous / Palatin Technologies
No trials found
PL8331 / Palatin Technologies
No trials found
PL9654 / Palatin Technologies
No trials found

Download Options